Terms: = Germ cell tumor AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Clinical Outcome
4 results:
1. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract] [Full Text] [Related]
2. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
[TBL] [Abstract] [Full Text] [Related]
3. Preexisting mek1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract] [Full Text] [Related]
4. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
Calabrese C; Frank A; Maclean K; Gilbertson R
J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
[TBL] [Abstract] [Full Text] [Related]
